Trade Mark Journal No.2026/015 10 April 2026

WO0000001909429 (5,10,44)

Office of origin: Denmark

Date of International Registration:27 November 2025
Date of designation in the UK: 27 November 2025
Image for mark 1909429 DEYZOLY

International priority date claimed: 12 June 2025 (Denmark)
Class 5
Pharmaceutical preparations, namely for treatment and prevention of stomach and bowel-related disorders and gastrointestinal diseases and disorders in humans, such as short bowel syndrome (SBS); medical preparations, namely for treatment and prevention of stomach and bowel-related disorders and gastrointestinal diseases and disorders in humans, such as short bowel syndrome (SBS); pharmaceutical preparations, namely for treatment of human patients suffering from CHI (Congenital HyperInsulinism) and/or hypoglycemia; medical preparations for the treatment of human patients suffering from CHI (Congenital HyperInsulinism) and/or hypoglycemia.
Class 10
Devices for introducing pharmaceutical preparations, namely for treatment and prevention of stomach and bowel-related disorders and gastrointestinal diseases and disorders in humans, such as short bowel syndrome (SBS), and parts and fittings therefor; devices for introducing pharmaceutical preparations, namely for treatment of human patients suffering from CHI (Congenital HyperInsulinism) and/or hypoglycemia, and parts and fittings therefor.
Class 44
Medical and pharmaceutical services, namely in relation to treatment and prevention of stomach and bowel-related disorders and gastrointestinal diseases and disorders in humans, such as short bowel syndrome (SBS); medical and pharmaceutical advice, namely in relation to treatment and prevention of stomach and bowel-related disorders and gastrointestinal diseases and disorders in humans, such as short bowel syndrome (SBS); medical and pharmaceutical services, namely in relation to treatment of human patients suffering from CHI (Congenital HyperInsulinism) and/or hypoglycemia; medical and pharmaceutical advice, namely in relation to treatment of human patients suffering from CHI (Congenital HyperInsulinism) and/or hypoglycemia.

Zealand Pharma A/S

Representative: PATRADE A/S, Ceresbyen 75, DK-8000 Aarhus C, DENMARK